The KRAS mutant population has been undruggable for 40 years. G12C inhibitors and immunotherapy are the beginning of success. It is necessary to summarize the successful experience of the existing treatment model and explore the direction of the next treatment. In this review, we discuss the latest developments in targeted therapy and immunotherapy for KRAS-mutation NSCLC, aiming to provide direction or enlightenment for future treatment strategies.
We use cookies on our website to ensure you get the best experience. Read more about our cookies here.
RSS feed for
Preprints: The Multidisciplinary Preprint Platform
Paste the URL in your RSS reader:
https://www.preprints.org/rss
If you want to subscribe our website in subject-wide, you could find the URL by choosing in the following: